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indicators for the Clearing House and the measures could complement indicators
on clinical quality of providers from the NIH Promis initiative in the United States
(or the NHS Proms in the UK).METHODS: The concept development is relevant for
chronic care. Five domains represent outpatient drug care: information, commu-
nication access, trust and clinical quality. Four process measures and one access
measure are proposed with series of 5 -7 items, tested on pharmacy delivery sys-
tems and dispensing doctors.The trust indicator has been identified as critical for
the US drug delivery system and discussed as an example. RESULTS: Trust ad-
resses the potential patient mistrust when cost interfere with clinical judgement.
The process measure is calculated for prescribing and treatment decisions for
Hypertension, Diabetes and Asthma.It is a rate base measure . The Facct scoring
method is modified to integrate minima in low score values. Mean scores are cal-
culated on samples per practice. Missing values are replaced by mean value. The
evidence from the UK PCT on a scale of 0-100, for three practices show scores of
66.78; 63.82;73.92 and 67.72 for the whole sample with a Cronbach of 0.70.
CONCLUSIONS:A composite indicator is envisaged for diffferent decision points in
clinical practices. It is to be linked to clinical decision points from the Adaptive
Knowledge Platform (AKP) (Huttin, Liebamn, 2011) on breast cancer and could fit
the requirements for the 12 rules for EGD in cancer. Validations in additional or-
ganisations of care and delivery systems are planned in further validation stages.
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HISTORICAL TRENDS IN OUTCOMES FOLLOWING AORTIC AND MITRAL HEART
VALVE REPLACEMENT PROCEDURES: A POPULATION-BASED STUDY OF 29,582
MEDICARE PATIENTS FROM 1997 TO 2009
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OBJECTIVES: To serve as comparative data for percutaneous valve replacements,
this study sought to characterize the historical outcomes for aortic andmitral valve
replacement surgery in a large, nationally representative population. METHODS:
Patients undergoing aortic ormitral valve replacement were identified from the 5%
national Medicare data (1997-2009) using ICD-9-CM codes 35.21 to 35.24. The sub-
sequent rates of mortality, mechanical complications, infection, and valve re-im-
plantation/reoperation, and infective endocarditis were evaluated. Hospitalization
charges and reimbursements (in Jan 2011 dollars) for the index procedurewere also
assessed. RESULTS: The patient cohort included 12,202 aortic bioprosthesis, 9,757
aortic mechanical valves, 3,222 mitral bioprosthesis, and 4,401 mitral mechanical
valves. The ten-year Kaplan-Meier mortality, mechanical complication, infection,
re-implantation/reoperation, and infective endocarditis rates for aortic biopros-
thesis were 64.4%, 4.41%, 4.54%, 1.50%, and 8.34%, respectively, and for aortic me-
chanical valves were 63.9%, 5.23%, 4.71%, 1.84%, and 9.08%, respectively. The cor-
responding ten-year Kaplan-Meier rates formitral bioprosthesiswere 74.8%, 8.02%,
6.29%, 2.81%, and 12.90%, respectively, and for mitral mechanical valves were
64.7%, 7.60%, 6.06%, 2.87%, and 12.24%, respectively. The average hospitalization
reimbursements for procedures involving aortic bioprostheses, aortic mechanical
valves, mitral bioprostheses, and mitral mechanical valves were $54.3k, $54.6k,
$64.1k, and $62.2k, respectively. CONCLUSIONS: The crude risks of mortality and
complications, as well as payer costs, were found to be higher for mitral valve
replacements compared with aortic valve replacements. This study provides base-
line data for evaluating the comparative effectiveness of percutaneous valve re-
placement to “traditional” approaches, especially since the percutaneous ap-
proach may have inherently different levels of performance or expanded
indications.
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ADMISSION TO CORONARY ANGIOGRAPHIC CATHETERIZATION IN ARMENIA
AT NORK MARASH MEDICAL CENTER: CHARACTERISTICS AND OUTCOMES
Perikhanyan A
Nork Marash Medical Center, Yerevan, Armenia
OBJECTIVES: The importance of avoiding unnecessary diagnostic invasive angiog-
raphy is emphasized based on risks associated with test and costs. At the same
time, early interventions are important to reduce negative outcomes of coronary
artery disease (CAD). Objective of this study was to analyze the characteristics and
outcomes of cases with possible CAD that underwent coronary angiography cath-
eterization (CAG) from December 2006 to February 2007 consecutively in Nork
Marash Medical Center (NMMC). METHODS: This was a retrospective study of
newly admitted cohort. Predefined exclusion criteria were CAG in other clinic, CAG
for other then CAD reasons and non Armenian residency. RESULTS: Only 200 re-
cordswere corresponding to the criteria. Themean age of caseswas 52.9110 years
and 85% were males (RR0.93). The mean age of women was higher (60 vs 50).
Only 10.5% of participants had normal BMI. Current smokers comprised 60 %(
RR1.17), 74% had hypertension (RR1.165), 30.5% hypercholesterolemia (RR2.5)
and 14.5%DiabetesMellitus (RR4.26). In 26(13%) cases catheterization detected no
CAD at all and 13(6.5%) patients had stenosis50%. Most catheterizations were
elective (68%).There were 2 urgent admissions among patients with CAD50%.
Significantly diseased left anterior descending (LAD) proximal was detected most
frequently (52%).Among patients with stenosis50% 24% of cases underwent PCI,
75% CABG, and 5% bridge to CABG procedure. Thirty two people (20%) were not
treated with revascularization: among them 7 (21.9%) with multivessel disease.
15% of patients with indication to revascularization refused to be treated with any
of procedures. CONCLUSIONS: There is gender inequality in CAG utilization, early
cholesterol control should be encouraged by primary care professionals, patient
preferences play significant role in a treatment decision process in Armenia.
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DOES CURRENT PERCEPTION THRESHOLD TEST CAN DIFFERENTIATE
CATEGORIES OF MECHANICAL NECK DISORDER?
Uddin Z, MacDermid JC, Galea V, Gross AR, Pierrynowski M
McMaster University, Hamilton, ON, Canada
OBJECTIVES: To differentiate three types of Mechanical Neck Disorders (MND) by
Current Perception Threshold (CPT). Specific aims were to: 1) Look whether differ-
ences in CPT exist in MND categories, and 2) Estimate the predicted probability of
the neurological symptoms in type-3 of MND. METHODS: The study design was a
laboratory based cross-sectional discriminative analysis. Patients with MND (N 
106) were assessed for CPT into three groups: MND-mixed (N60), MND-2 (N29),
MND-3 (N17). CPT testing was performed in a standard Quantatative Sensory
Testing laboratory. A one-way ANOVA with post hoc was done for compare the
mean CPT score between the groups. An independent sample t-test was done to
compare the mean CPT and estimated effect size between MND-2 and MND-3
group. The discriminative analysis predicted the group membership in one of the
categories. A binary logistic regressionmodel predicted probability of higher CPT in
MND-3, where CPT score counted as the risk factor to having neurological symp-
toms. A Receiver Operating Characteristic (ROC) curve was created from predicted
probability by binary covariate. RESULTS: Mean CPT differed significantly across
the three groups (F 2, 96  6.69, p  0.002), with a significant higher preference
rating in MND-3 (p  0.004). Moderate discriminates and a small to medium effect
size found between theMND-2 andMND-3. Model discrimination (betweenMND-2
and MND-3) showed 86.2% specificity and 64.7% sensitivity, where an area under
the ROC curvewas 0.836 (95% CI 0.716 - 0.956, p 0.000). CONCLUSIONS: CPT test
was capable of differentiate MND categories. CPT might be a potential tool for
evaluating neurological involvement or hypersensitivity in neck pain.
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QUALITATIVE MOLECULAR TESTS FOR CONFIRMATION OF THE DIAGNOSIS OF
HEPATITIS C IN SEROPOSITIVE PATIENTS: A SYSTEMATIC REVIEW
Oliveira IG, Pereira C, Portela M
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OBJECTIVES: Hepatitis C represents a serious Public Health problem. In approxi-
mately 80%of cases, the disease becomes chronic and the diagnosis can sometimes
be made before the disease becomes severe. In 1993, the Brazilian government
adopted a screening system with serological kits for hepatitis C diagnosis in blood
donors. A positive screening, however, should be confirmed with another type of
test since they do not distinguish active infection from past infection. So, molecu-
lar tests are very important to establish actual viremia and the hepatitis c diagno-
sis. Many guidelines throughout the world recommend the molecular test in vari-
ous settings, including the confirmation of HCV in seropositive people. There are
different qualitative molecular tests available for detecting HCV. The aim of this
studywas to conduct a systematic reviewof the accuracy of these different tests for
confirmation of the diagnosis of HCV in seropositive people. METHODS: We
searched MEDLINE, SCOPUS and the Cochrane Library. QUADAS was the tool used
for quality assessment of the studies.RESULTS:The search resulted in 1222 articles
for evaluation. Only 2 studies were included in the systematic review, according to
the established inclusion and exclusion criteria. Both COBAS AMPLICOR and AM-
PLICOR tests had high sensitivity and specificity in one of the studies. The second
study, presented accuracy data regarding an “in house” PCR test, which presented
overall accuracy of 75%. CONCLUSIONS: Although we identified many articles in
our search, the vast majority addressed analytical sensitivity, therefore not meet-
ing our criteria, especially because they did not present accuracy data according to
an established a gold standard. Furthermore, the 2 studies included did not present
a good methodological quality according to QUADAS. These findings show the
urgent need of studies with appropriate design for extraction of accuracy data of
molecular tests.
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OBJECTIVES: The use of K-ras testing in clinical decision-making has grown over
the past few years. The objective of this study was to evaluate, in a real world
context, the trends anddiagnostic findings of K-ras testing usingmanaged care and
EMR data. METHODS: The Georgia Cancer Specialists Database EMR (2005-2010)
and administrative data from theMarketScan and IMPACT database(s) was used to
select patients with newly diagnosed colorectal cancer (CRC). We looked for trends
in use of K-ras in relation to timing of chemotherapy administration. The EMR data
provided information on k-ras mutation type. RESULTS: In MarketScan, of the
23,548 patients with a diagnosis of CRC, 1,730 (7.3%) patients had a test ordered for
K-ras between 2005 and 2010. The number of patients receiving K-ras increased
with line of therapy: first line 336 patients (8.2%) of 4098 treated, second line 455
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patients (15.2%) of 2984 treated, and third line 529 patients (33%) of 1603 treated.We
found similar results using the IMPACT database: 2,256 (7.8%) CRC patients had a
test ordered for K-ras between 2005 and 2010. K-ras testing increased with line of
therapy: first line 244 patients (7.8%), second line 510 (14.6%), and third line 650
patients (33.1%). EMR lab results from stage IV disease (n349) consisted of 15%
mutated type, 60% unknown and 25% wild type. For confirmed test results wild
type represented 62.5% and mutated type 37.5%. CONCLUSIONS: Over the last six
years, use of K-ras testing has increased in use in patients with CRC. The increase
has occurred in later lines of therapy. The timing occurring late in therapy may
limit the use of agents specific for this test.
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OBJECTIVES: The aim of this study is to evaluate the accuracy of non-invasive
diagnosis methods for ischemic heart disease in patients with chest pain.
METHODS:A retrospective cohort study was performed on new patients who have
not received any diagnosis of ischemic heart disease or treatment before among
those over 30 years of agewho visited the cardiology outpatient clinic between 2006
to 2008 in a single medical institution. Among non-invasive diagnostic methods,
stress ECG(sECG), myocardial SPECT, and CT coronary angiography(CTCA) were
included in our study. Since coronary angiography(CAG) was not performed in all
patients, the comparison of test accuracy was calculated by correcting referral bias
to CAGdepending onnon-invasive test results based on the Bayes Theorem, and by
reflecting the 1-year follow-up results. RESULTS: Among 4743 patients selected,
2485 patients received more than one of the following non-invasive tests: sECG,
SPECT, and CTCA for differential diagnosis. sECG was performed in 853 pa-
tients(34.3%), SPECT in 997 patients(40.1%), andCTCA in 635 patients(25.6%). A total
of 592 patients(23.8%) received CAG among the 2485 patients. Test indices adjusted
for referral bias using the 2 methods were a sensitivity of 49% or 80% in sECG, 46%
or 75% in SPECT and 57% or 88% in CTCA, a specificity of 65% or 62%, 81% or 78% in
SPECT and 96%or 81% inCTCA. A likelihood ratio for a positive testwere 1.39 or 2.08
in sECG, 2.47 or 3.38 in SPECT and 14.14 or 4.65 in CTCA, and a likelihood ratio for a
negative test were 0.79 or 0.33 in sECG, 0.66 or 0.32 in SPECT and 0.45 or 0.14 in
CTCA. CONCLUSIONS: In conclusion, the accuracy of diagnosing ischemic heart
disease was the highest in CTCA, followed by myocardial SPECT and sECG by cor-
recting referral bias to CAG.
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LONG-TERM CLINICAL OUTCOMES AFTER CORONARY BARE-METAL AND
DRUG-ELUTING STENTING
Yin S, Parente AK, Teigland C, Jones BT, Wang RH
MedAssurant Inc., Bowie, MD, USA
OBJECTIVES: To evaluate long-term clinical outcomes of elderly Medicare benefi-
ciaries who underwent non-emergent coronary stenting.METHODS: This popula-
tion-based prospective study analyzed patients in a large nationally representative
administrative claims database. The sample consisted of Medicare patients aged
65 who underwent a non-emergent coronary stent between 2006 and 2010. Pa-
tients were identified by existence of a hospital claim for a bare metal stent (ICD-
9-CM procedure code 36.06) or drug-eluting stent (ICD-9-CM procedure code 36.07
or codes 36.06 and 36.07). Eligible patients were followed one to five years after
stenting to assess risk of revascularization, myocardial infarction (MI), coronary
artery bypass surgery (CABG), and death. Long-term clinical outcomes were based
on HEDIS 2010 technical specifications. RESULTS: The study population included
26,023 patients that underwent a coronary bare-metal stent (female  40.15%, age
 75.38 ( 6.66), history ofMI 7.97%, history of CABG 1.01%) and 74,448 patients
that underwent a coronary drug-eluting stent (female  40.17%, age  73.78 (
6.19), history of MI  7.39%, history of CABG  1.27%). Patients with drug-eluting
stents had a lower risk of revascularization (29.57% vs. 31.65%, p  0.001), CABG
(1.40% vs. 2.57%, p  0.001), and mortality (4.96% vs. 9.25%, p  0.001) within one
year follow-up after stenting. There was no significant difference in the risk for MI
within one to four years follow-up (3.35% vs. 3.29%, p  0.05), but there was a
significant difference in risk of MI at five year follow-up (7.33% vs. 3.36%, p 0.001).
Mortality rates significantly increased over time in patientswith a bare-metal stent
whilemortality rates for thosewith a drug-eluting stent remained relatively stable.
CONCLUSIONS: The use of drug-eluting stents was significantly correlated with a
decline in long-term risk of revascularization, CABG,MI anddeath in comparison to
bare-metal stents.
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EFFICACY OF SYSTEMIC HYPERBARIC OXYGEN THERAPY FOR NON-HEALING
DIABETIC ULCERS OF THE LOWER LIMB: SYSTEMATIC REVIEW AND META-
ANALYSIS
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OBJECTIVES: About 10-15% of individuals with diabetes mellitus develop foot ul-
cers which precede 85% of amputations. Increased oxygen exposure, through the
use of hyperbaric oxygen therapy (HBOT), has been suggested to encourage ulcer
healing thus reducing the risk of amputation. The objective of this systematic
review is to evaluate the efficacy of systemic HBOT for non-healing ulcers of the
lower limb in diabetes patients. METHODS: A systematic search of the published
literature was conducted using controlled and keyword terms focusing on “HBOT”
and “lower limb diabetic ulcers”. Databases searched included Medline, EMBASE,
CINAHL, PubMed, Wiley’s Cochrane Library, and Biosis. Randomized controlled
trials (RCTs) and observational studies were included and no year or language
limits were employed. Two reviewers screened the articles. Pooled estimates of
outcomes were calculated using Review Manager when appropriate. RESULTS: Of
the 543 citations identified, 152 articles underwent full-text review. Data was ab-
stracted from 27 publications (7 RCTs, 9 comparative observational, and 11 non-
comparative observational studies). Primary outcomes of rates of amputation (ma-
jor or minor) and wound healing were identified. Relative risk (RR) estimates from
RCTs in the pooled analysis reflect a significant reduction inmajor amputation (RR
 0.32, 95% CI 0.11 to 0.91) with HBOT. For the proportion of unhealed wounds,
HBOT is also favoured (RR  0.45, 95% CI 0.32 to 0.64). CONCLUSIONS: The limited
RCT evidence surrounding the efficacy of HBOT favours the use of HBOT for non-
healingwounds of the lower limb for diabetes patients. Rigorous clinical trials with
larger sample sizes, however, need to be conducted to more conclusively establish
the benefits and harms of treating diabetic lower limb ulcers with HBOT.
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AN INNOVATIVE DISCUSSION ON PET- SCAN: IS IT THE POSITRON EMISSION
TOMOGRAPHY A COST EFFECTIVE ALTERNATIVE IN THE PRE-TREATMENT
EVALUATION OF CERVICAL CARCINOMA COMPARED TO FIGO STAGING?
Burbano-levy X1, Schroeder ED2, Schuman SI2, Castillo R2, Simpkins F2, Diaz JP2
1Florida International University, Miami, FL, USA, 2University of Miami, Miami, FL, USA
OBJECTIVES: The increasing use of both PET scan and surgical lymph node evalu-
ation in the cervical cancer (CC) treatment has led to a clinical debate. The objective
of this study is to provide a cost analysis of routine PET imaging in the work-up of
CC. METHODS: A decision-tree model was designed to compare pre-treatment
evaluation including PET-scan versus FIGO staging. Primary outcome was correct
primary treatment (CPT) due to the use of PET or FIGO. Cost effectiveness ratios
were calculated and results were expressed in terms of incremental cost effective-
ness ratio (ICER). The model used the SEER 2011 database (n12,200), for number,
incidence, and stage distribution of CC. Medicare reimbursement rates were used
for costs. Lymph nodemetastasis rates for each stage, and performance character-
istics of PET were abstracted from published data. Cited values were used and
varied over for sensitivity analysis. RESULTS: The addition of PET-scan to FIGO
clinical staging for IA1 CC resulted in 6(0.5%) more CPTs than FIGO staging at
baseline. In stage IA2, 75(6%) more CPT were performed and 187(14%) in stage IB1,
and an additional 322(24%) in IB2. In stage IIA, PET-scan resulted in an additional
50(3%) CPT (ICER$75,575), compared to 234(12%) CPT (ICER$61,509) in stage IIB,
and 333(26%) additional CPT in stage IIIA, (ICER $48,293). In stage IIIB and IVA the
addition of PET resulted in 240(19%) more CPT, and 41(8%) additional CPT in stage
IVA (ICER$52,791 vs.$71,810). Outcomes were sensitive to changes in prevalence
and PET performance in the sensitivity analysis.CONCLUSIONS:Routine pre-treat-
ment PET-scan may be cost effective for stage IA2-IB2 CC. The inclusion of PET-
scan in the pre-treatment evaluation of stage I CC increased the number of CPT
with an elevated ICER. The findings of this model need to be validated in the
clinical-setting to generate knowledge on best resources’ allocation.
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THE ROLE OF BIOMARKERS IN LUNG CANCER SCREENING: A SYSTEMATIC
REVIEW AND META-ANALYSIS
Chien CR, Wang PH
China Medical University Hospital, Taichung, Taiwan
OBJECTIVES: Low dose computed tomography (CT) is the current recommended
lung cancer screening modality for selected high risk population. The role of bio-
markers is not clear. The objective of our study is to investigate the role of biomark-
ers in lung cancer screening via a systematic review andmeta-analysis.METHODS:
A systematic review is performed by reviewing primary studies focusing on bio-
markers for lung cancer screening using the following keywords (lung cancer) AND
((screen*) OR (diagnosis) OR (diagnostic) OR (prediagnostic) OR (detection) OR (pre-
dict*) OR (development)) AND ((biomarker) OR (blood) OR (serum) OR (sera) OR
(plasma) OR (antibodies) OR (urin*) OR (sputum) OR (exhale*) OR (volatile) OR (epi-
thelium)OR (epithelial) OR (bronchial) OR (airway)) in the title/abstract in Pubmed®
on December 31, 2011. We further limited our search to clinical trials, meta-anal-
ysis, or randomized controlled trials published for the past 5 years in English. Two
independent reviewers identified studies compatible for selection criteria and data
extraction after consensuswas reached.Manual searching for relevant studieswas
also performed from relevant studies. A randomeffectmodel was used to calculate
the pooled diagnostic performance of biomarker screening. RESULTS: Among the
identified studies (n172), three studies were included. In total, 1932 participants
received various kinds of biomarkers screening. By using these biomarkers to dif-
ferentiate cancer from non-cancer, the estimated pooled sensitivity and specificity
with 95% confidence interval was 40% (24%  57%) and 96% (94%  97%)
respectively. CONCLUSIONS: The diagnostic performance of biomarkers for lung
cancer screening is fair based on very limited data as found in this systematic
review. The role of biomarkers in lung cancer screening deserves further studies.
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BUDGET IMPACT OF CONVERTING STANDARD TREATMENT OF MENORRHAGIA
FROM ROLLERBALL TO THERMAL BALLOON ABLATION IN CANADIAN
HOSPITALS
Goldstein LJ
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